PRT12396

Current understanding

To be populated as evidence accumulates.

February 3 — Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor: cross-connection with prt12396-jak2v617f-mutant-selective-inhibitor: Potential duplicate pages for the same compound — consider merging into the more descriptive ‘prt12396-jak2v617f-mutant-selective-inhibitor’ slug. (novelty: 4)
2026-03-31 — A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms: First-in-human Phase 1 open-label, multi-center dose-escalation and dose-expansion trial launched to evaluate safety, tolerability, PK, and preliminary efficacy of PRT12396 in high-risk polycythemia vera and myelofibrosis (mechanism not publicly disclosed). (novelty: 4)